```
                E PIPAMPERONE/CN
                SET EXPAND CONTINUOUS
L1            1 S E3
                E ESCITALOPRAM/CN

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2011 ACS on STN
RN   128196-01-0  REGISTRY
ED   Entered STN:  13 Jul 1990
CN   5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-
     fluorophenyl)-1,3-dihydro-, (1S)-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   5-Isobenzofurancarbonitrile, 1-[3-(dimethylamino)propyl]-1-(4-
     fluorophenyl)-1,3-dihydro-, (S)-
OTHER NAMES:
CN   (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-
     dihydroisobenzofuran-5-carbonitrile
CN   (+)-(S)-Citalopram
CN   (+)-Citalopram
CN   (S)-Citalopram
CN   Escitalopram
CN   S-(+)-Citalopram
CN   Seroplex
FS   STEREOSEARCH
MF   C20 H21 F N2 O
CI   COM
SR   CA
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH, IPA,
       MEDLINE, MRCK*, PATDPASPC, PS, REAXYSFILE*, RTECS*, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)

Absolute stereochemistry.  Rotation (+).
```




```
L2            1 S E15

     FILE 'CAPLUS' ENTERED AT 09:37:00 ON 11 JUL 2011
L3           23 S L1 AND L2
L4            1 S L3 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L5            7 S US 20070078162/PN
                E 5-HT REUPTAKE INHIBITORS/IT
                E 5-HT REUPTAKE INHIBITORS/CT
L6         4398 S E39
L7           14 S L1 AND L6
L8            7 S L7 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
```

L8 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN

AB The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-...) using compds. and compns. of compds. having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds. The combination can also be used to augment the therapeutic effect of or to provide a faster onset of the therapeutic effect of a selective serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitor, an NK1 antagonist, or a musculoskeletal disease-treating COX-2 inhibitor. Pharmaceutical compns. are also claimed.

ACCESSION NUMBER: 2005:474936 CAPLUS Full-text
DOCUMENT NUMBER: 143:1315
TITLE: Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
INVENTOR(S): Buntinx, Erik
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 725,965.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050119248	A1	20050602	US 2004-752423	20040106
US 7855195	B2	20101221		
US 20050119253	A1	20050602	US 2003-725965	20031202
US 7884096	B2	20110208		
US 20050119249	A1	20050602	US 2004-803793	20040318
US 20050203130	A1	20050915	US 2004-984683	20041109
CA 2547639	A1	20050616	CA 2004-2547639	20041202
WO 2005053796	A1	20050616	WO 2004-BE172	20041202

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1708790 A1 20061011 EP 2004-801138 20041202
<--
EP 1708790 B1 20100421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU
JP 2007513095 T 20070524 JP 2006-541759 20041202
<--
JP 4571645 B2 20101027
AT 464901 T 20100515 AT 2004-801138 20041202
<--
PT 1708790 E 20100709 PT 2004-801138 20041202
<--
EP 2272514 A1 20110112 EP 2010-159625 20041202
<--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU
US 20070078162 A1 20070405 US 2006-580962 20060531
<--
PRIORITY APPLN. INFO.: US 2003-725965 A2 20031202
<--
CA 2003-2451798 A 20031202
<--
EP 2003-447279 A 20031202
<--
EP 2004-447001 A 20040105
US 2004-752423 A2 20040106
CA 2004-2461248 A 20040318
EP 2004-447066 A 20040318
US 2004-803793 A2 20040318
EP 2004-25035 A 20041021
JP 2004-349085 A 20041104
US 2004-984683 A 20041109
CA 2004-2487529 A 20041115
EP 2004-801138 A3 20041202
WO 2004-BE172 W 20041202

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

INCL 514217000; 514220000; 514259410; 514469000; 514317000; 514649000

IPCI A01N0043-46 [I,A]; A01N0043-26 [I,A]; A01N0033-02 [I,A]; A01N0033-24 [I,A]; A61K0031-535 [I,A]; A61K0031-445 [I,A]; A61K0031-335 [I,A]

IPCR A61K0031-00 [I,A]; A61K0031-343 [I,A]; A61K0031-445 [I,A]; A61K0031-4545 [I,A]; A61K0031-519 [I,A]; A61K0031-55 [I,A]; A61K0031-551 [I,A]; A01N0043-46 [I,A]; A01N0033-02 [I,A]; A01N0033-24 [I,A]; A01N0043-26 [I,A]; A61K0031-335 [I,A]; A61K0031-535 [I,A]

NCL 514/217.000; 514/220.000; 514/259.410; 514/317.000; 514/469.000; 514/649.000; 514/232.800; 549/467.000

CC 1-11 (Pharmacology)
Section cross-reference(s): 63

IT 5-HT reuptake inhibitors
Antipsychotics

(as second compound; treating underlying dysregulation of emotional functionality of mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists)
IT 1841-19-6, FLUSPIRILENE 1893-33-0, PIPAMPERone 5786-21-0, CLOZAPINE 26615-21-4, ZOTEPINE 75558-90-6, AMPEROZIDE 85650-56-2, ORG 5222 87691-91-6, TIOspirone 106266-06-2, RISPERIDone 106516-24-9, SERTindole 127625-29-0, FANANSERIN 129029-23-8, OCAPERIDone 132539-06-1 139290-65-6 146939-27-7, ZIPRASIDone 158985-00-3, L 745870 169167-86-6, S16924 170858-34-1, PNU-101387G 200398-40-9, S18327
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating underlying dysregulation of emotional functionality of mental
disorders using D4 and 5-HT2A antagonists, inverse agonists or partial
agonists)

		E	SSRI/IT
L9	656	S	E51-E52,E53
L10	0	S	L1 AND L9
L11	215	S	SSRIS/IT
L12	0	S	L1 AND L11
L13	7615	S	((SEROTONIN) (S) REUPTAKE (S) (INHIBIT?))
L14	12	S	L1 AND L13
L15	5	S	L14 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L16	1	S	L15 NOT L8
		E	5-HT ANTAGONISTS/IT
L17	3812	S	5-HT ANTAGONISTS/IT
L18	34	S	L2 AND L17
L19	7	S	L18 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L20	7	S	L19 NOT (L8 OR L15)

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2011 ACS on STN
AB The present invention relates to the use of compds. and compns. of compds. having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compds. E.g., simultaneous administration of 10 μmol/kg citalopram with 1 μmol/kg RS 102221 or Lu 27121 showed significant enhancement of the effect of citalopram in rats.
ACCESSION NUMBER: 2001:434808 CAPLUS Full-text
DOCUMENT NUMBER: 135:41033
TITLE: The combination of a serotonin reuptake inhibitor and
a 5-HT2C antagonist, inverse agonist or partial agonist
INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Wikstroem, Hakan Wilhelm; Den Boer, Johan Antonie; Bosker, Fokko
Jan; Westerink, Bernard Hendrik Cornelis; Bogeso,

	Klaus Peter; Hogg, Sandra; Mork, Arne
PATENT ASSIGNEE(S):	H. Lundbeck A/s, Den.
SOURCE:	PCT Int. Appl., 29 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041701	A2	20010614	WO 2000-DK671	20001206
WO 2001041701	A3	20011213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393470	A1	20010614	CA 2000-2393470	20001206
AU 2001018511	A	20010618	AU 2001-18511	20001206
US 20020103249	A1	20020801	US 2000-731411	20001206
EP 1237553	A2	20020911	EP 2000-981174	20001206
EP 1237553	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 2002001512	T2	20020923	TR 2002-1512	20001206
BR 2000016385	A	20030218	BR 2000-16385	20001206
HU 2002003586	A2	20030328	HU 2002-3586	20001206
HU 2002003586	A3	20050228		
JP 2003516326	T	20030513	JP 2001-542871	20001206
CN 1433313	A	20030730	CN 2000-818827	20001206
EP 1396267	A2	20040310	EP 2003-27672	20001206
EP 1396267	A3	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 314849	T	20060215	AT 2000-981174	20001206
PT 1237553	E	20060531	PT 2000-981174	20001206
ES 2255519	T3	20060701	ES 2000-981174	20001206
EP 1782813	A1	20070509	EP 2007-103057	20001206

<--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
IL 149994 A 20070724 IL 2000-149994 20001206
<--
NZ 545907 A 20070727 NZ 2000-545907 20001206
<--
EP 2036564 A1 20090318 EP 2008-21043 20001206
<--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE, TR, AL, LT, LV, MK, RO, SI
CN 101406465 A 20090415 CN 2008-10149947 20001206
<--
ZA 2002004391 A 20030901 ZA 2002-4391 20020531
<--
NO 2002002657 A 20020726 NO 2002-2657 20020605
<--
MX 2002005613 A 20021213 MX 2002-5613 20020606
<--
US 20030032636 A1 20030213 US 2002-165196 20020606
<--
KR 832026 B1 20080523 KR 2002-7007231 20020607
<--
HR 2002000527 A2 20041231 HR 2002-527 20020617
<--
BG 106895 A 20030430 BG 2002-106895 20020702
<--
IN 213140 A1 20080331 IN 2002-CN1026 20020703
<--
AU 2006200878 A1 20060323 AU 2006-200878 20060301
<--
US 20070105843 A1 20070510 US 2006-539100 20061005
<--
US 20090176808 A1 20090709 US 2009-406226 20090318
<--
AU 2009202463 A1 20090709 AU 2009-202463 20090619
<--
PRIORITY APPLN. INFO.: US 1999-169245P P 19991206
<--
AU 2001-18511 A3 20001206
<--
CN 2000-818827 A3 20001206
<--
EP 2000-981174 A3 20001206
<--
EP 2003-27672 A3 20001206
<--
EP 2007-103057 A3 20001206
<--
US 2000-731411 B1 20001206
<--
WO 2000-DK671 W 20001206
<--
US 2002-165196 B1 20020606
<--
AU 2006-200878 A3 20060301
US 2006-539100 A3 20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IPCI A61K [ICM,7]
IPCR A61K [I,S]; A61K0031-00 [I,A]; A61K0031-135 [I,A]; A61K0031-137 [I,A]; A61K0031-138 [I,A]; A61K0031-15 [I,A]; A61K0031-343 [I,A]; A61K0031-405 [I,A]; A61K0031-4439 [I,A]; A61K0031-445 [I,A]; A61K0031-4525 [I,A]; A61K0031-496 [I,A]; A61K0031-513 [I,A]; A61K0031-519 [I,A]; A61K0031-55 [I,A]; A61K0031-551 [I,A]; A61K0033-36 [I,A]; A61K0045-06 [I,A]; A61P0001-14 [I,A]; A61P0003-04 [I,A]; A61P0025-20 [I,A]; A61P0025-22 [I,A]; A61P0025-24 [I,A]; A61P0025-28 [I,A]; A61P0025-30 [I,A]; A61P0043-00 [I,A]; G01N0033-94 [I,A]
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 5-HT antagonists
(5-HT2C; combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist)
IT 50-49-7, Imipramine 303-49-1, Clomipramine 24219-97-4, Mianserine 54739-18-3, Fluvoxamine 59859-58-4, Femoxetine 61869-08-7, Paroxetine 79617-96-2, Sertraline 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 87051-43-2, Ritanserin 93413-69-5, Venlafaxine 106516-24-9, Sertindole 119356-77-3, Dapoxetine 120444-71-5, Deramciclane 128196-01-0, Escitalopram 158942-04-2, SB 206553 161178-10-5, YM 35992 181632-25-7, SB 242084 200940-22-3, SB 243213 210821-63-9, Org 12962 344454-50-8, SB 228356 344454-51-9, Ro 60-0795 344454-52-0, Org 38457 344454-70-2, EGIS 8465
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist)

L21 211 S (5-HT-2A?)
L22 0 S L2 AND L21
L23 5563 S (5-HT2A?)
L24 35 S L2 AND L23
L25 8 S L24 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L26 4 S L25 NOT (L8 OR L15 OR L19)

FILE 'CAPLUS' ENTERED AT 10:55:12 ON 11 JUL 2011
L27 1 S US 20070248697/PN

E PIPAMPERONE/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
RN 1893-33-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[4-(4-fluorophenyl)-4-oxobutyl]-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[3-(p-fluorobenzoyl)propyl]-
(7CI,
8CI)
OTHER NAMES:
CN 1'-[3-(p-Fluorobenzoyl)propyl][1,4'-bipiperidine]-4'-carboxamide
CN 1-(p-Fluorophenyl)-4-(4-piperidino-4-carbamoylpiperidino)-1-butanone
CN 4'-Fluoro-4-[4-N-piperidino-4-carbamidopiperidino]butyrophenone
CN 4'-Fluoro-4-{N-[4-(N-piperidino)-4-carbamido]piperidino}butyrophenone
CN Dipiperal
CN Dipiperon
CN Dipiperone
CN Floropipamide
CN McN-JR 3345
CN Pipamperone
CN R 3345
MF C21 H30 F N3 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS,
BIOTECHNO,
CA, CAPLUS, CHEMCATS, CHEMLIST, DDFU, DRUGU, EMBASE, IPA, MEDLINE,
MRCK*, PS, REAXYSFILE*, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2,
USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: WHO



```
                SET EXPAND CONTINUOUS
L1              1 S E3

     FILE 'CAPLUS' ENTERED AT 15:36:21 ON 20 JUL 2011
L2              7 S US 20070078162/PN
L3            329 S L1
                  E ANXIETY/CT
L4          64940 S E15+ALL/CT
                  E E15+ALL/CT
L5          17114 S E29,E34
                  E ANXIOLYTICS/CT
                  E E38+ALL/CT
L6          12946 S E53,E59
                  E EMOTION/CT
                  E E63+ALL/CT
L7         148471 S E76,E80-E84
                  E MENTAL AND BEHAVIORAL DISORDERS/CT
                  E E87+ALL/CT
L8         258158 S E101-E105,E132-E195,E197
                  E ANTIPSYCHOTICS/CT
                  E E202+ALL/CT
L9         297254 S E229,E142-E242,E244-E245
                  E PSYCHOTROPICS/CT
                  E E255+ALL/CT
L10         77681 S E270-E273,E280,E291,E313,E321,E327-E328,E334
L11           217 S L3 AND (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)
L12           145 S L11 AND (PY<=2003 OR PRY<=2003 OR AY<=2003)
L13             0 S L3 (L) (L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)
```